Raptiva warnings updated.(Complications and side effects)(Brief Article)

The labeling for the immunosuppressive agent, Raptiva (efalizumab, from Genentech) has been updated with a warning regarding events of immune-mediated hemolytic anemia associated with the use of this drug. Reports of hemolytic anemia, some serious, diagnosed 4-6 months after the start ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!